Table 1.
Frequency of selected autoantibodies in the CSRG cohort
| n | % | Numbers not tested | |
|---|---|---|---|
| CENP-B | 285 | 36% | 162 |
| Centromere by IIF | 334 | 35% | 2 |
| CENP-A | 275 | 34% | 162 |
| Ro52/TRIM21 | 194 | 20% | 0 |
| RNA polymerase III | 144 | 19% | 188 |
| Topoisomerase I | 150 | 16% | 0 |
| PM/Scl | 53 | 7% | 188 |
| Ro60 | 53 | 6% | 0 |
| U1 RNP | 59 | 6% | 0 |
| Chromatin | 44 | 5% | 0 |
| Sm | 39 | 4% | 0 |
| SS-B/La | 26 | 3% | 0 |
| Jo-I | 6 | 1% | 0 |
| Ribosomal P | 14 | 1% | 0 |
N = 963. CENP, centromere protein; IIF, indirect immunofluorescence; PM/Scl, polymyositis/scleroderma (exosome) autoantigen; RNP, ribonucleoprotein; Sm, Smith autoantigen; SS-B, Sjögren syndrome antigen B or La.